Human papillomavirus and risk factors for cervical adenocarcinoma in the state of Pernambuco, Brazil

Telma Maria Lubambo Costa 1
https://orcid.org/0000-0002-2276-8112

Natália Lubambo 5
https://orcid.org/0000-0002-9665-9242

Sandra Herácio 2
https://orcid.org/0000-0003-0558-6111

Gustavo Fonseca de Albuquerque Souza 6
https://orcid.org/0000-0002-1794-701X

Melania Maria Ramos Amorim 3
https://orcid.org/0000-0003-1047-2514

Alex Sandro Rolland Souza 7
https://orcid.org/0000-0001-7039-2052

Paulo Roberto Eleutério Souza 4
https://orcid.org/0000-0002-9186-9849

Abstract

Objectives: to determine the incidence of the main high oncogenic risk types of the human papillomavirus (HPV) (16, 18, 31 and 33) and the risk factors for cervical adenocarcinoma.

Methods: a case-control study was carried out with 324 women (69 with adenocarcinoma and 260 healthy controls) between 2001 and 2014. Information on risk factors associated with adenocarcinoma were collected and the detection performed on HPV by using Polymerase Chain Reaction (PCR) method.

Results: adenocarcinoma was associated with age ≥40 years old (OR=2.95; 95%CI=1.13-7.71), ≤3 years of schooling (OR=2.34; 95%CI=1.02-5.37), presence of HPV (OR=6.75; 95%CI=2.41-18.91), women in menopausal status (OR=4.76; 95%CI:1.70-13.31), black race (OR=6.71; 95%CI= 2.11-21.32) and never had undergone cervical cancer screening (OR=9.92; 95%CI:2.41-40.81). And among the HPV types detected, HPV 18 was observed to be strongly associated with adenocarcinoma of the cervix (OR=99.1; 95%CI=12.96-757.78).

Conclusions: the factors associated with cervical adenocarcinoma were ≥40 years old, ≤3 years of schooling, black race, menopausal status, never had undergone cervical cancer screening and the presence of HPV.

Key words Adenocarcinoma in situ, Papillomaviridae, Molecular biology, Risk factors, uterine cervical neoplasms
Introduction

Cervical cancer is the fourth most common type of cancer worldwide, with 266,000 women’s death occurred in 2012.¹ In Brazil, cervical cancer is the third most common type of cancer in women and the highest in mortality, excluding non-melanoma skin, with an estimated incidence of 17.1 cases per 100,000 women in 2018.²

Oncotic cytology is the well-established method used for screening precursor lesions and cervical cancer.³ Even in developed countries with a good coverage, an increase has been observed in the incidence of cervical adenocarcinoma,² which is less common and more difficult to diagnose than squamous cell carcinoma, presenting more false negatives in screening, besides having a bad prognosis and unsatisfied therapeutic response.⁴

There has been an increase in the incidence of cervical glandular neoplasia over the past thirty years, with these now accounting for 24% of all cancer cases diagnosed in the United States annually.⁵ Of all invasive carcinomas of the uterine cervix, 27% are adenocarcinomas in their pre-invasive and invasive forms.⁶

Cervical adenocarcinoma is observed as an associated factor fornulliparity, excess weight, exogenous estrogen,³ better socioeconomic level, age <35 years⁷ and human papillomavirus (HPV) type 16 and 18.⁸

The causal agent associated with squamous cell carcinoma and adenocarcinoma of the uterine cervix is HPV. In addition to factors related to the infection itself such as viral load and whether it consists of a single or multiple infections are associated to other HPV factors that can influence the progression or the disappearance of the disease.⁹

Therefore, this present study was carried out to determine the associated factors to cervical adenocarcinoma and besides the frequency of HPV typesin a poor region of Latin America, thus contributing with useful information for an appropriate prevention and conduct for the patients.

Methods

An analytical, observational, case-control study was conducted. The study was based on the women’s data collected from the Serviço de Patologia Cervical do CAM-IMIP, (Cervix Pathology Service) at the Instituto de Medicina Integral Prof. Fernando Figueira (IMIP) between 2001 and 2014.

Sample size was calculated by using OpenEpi, version 2.3.1 (Atlanta, GA, USA), considering a smoking frequency of 50% in women with adenocarcinoma and 30% in the healthy controls.¹⁰ For a case/control proportion of 1:4, a power of 80% and a 5% significance level, 64 cases and 256 controls would be required. To compensate for possible losses, the sample was increased by 20%, 77 cases and 308 controls.

Cases included all women with histopathological diagnosis of adenocarcinoma in situ or invasive cervical, as identified at the cervix pathology record service, any patient with adenocarcinoma for paraffin blocks from biopsy or surgical specimens were excluded. The healthy controls consisted of women submitted to routine cervical cancer screening whose data were used in the control case study conducted by Mendonça et al.¹⁰ Women whose cytology findings included a diagnosis of atypical cells or who had abnormal findings at colposcopy including suggestion of invasion were excluded from the controls.

For this study, altered cytology was taken in consideration when the results were abnormal according to the Sociedade Brasileira de Citologia (Brazilian Cytology Society).³ Colposcopy was described as abnormal according to the definition established by the Sociedade Brasileira de Patologia do Trato Genital Inferior e Colposcopia (Brazilian Society of Pathology of the Lower Genital Tract and Colposcopy) and the International Federation for Cervical Pathology and Colposcopy (IFCPC).¹¹

Eligible participants were identified from the records in the Cytology Department and divided into two groups. The independent variables were collected from the medical records before their diagnosis on adenocarcinoma. Paraffin blocks for biopsy or surgical specimen were used for genotyping.

The variables evaluated were in situ and invasive adenocarcinoma, age (years), skin color/race, body mass index (Kg/m²), illiteracy, schooling, absence of the partner, place of residence, age at first sexual intercourse and number of partners. Other variables included the number of previous pregnancies, menopausal status, prior use of hormonal contraceptives, condom use, use of immunosuppressive drugs, chronic diseases, sexually transmitted infections, and smoking, underwent cancer screening and frequency of HPV types.

HPV genotype was obtained for the controls following the cytobrush sampling, with HPV-DNA testing was performed in six genotypes (HPV 16, 18, 31, 33, 6 and 11) using specific primer.¹⁰ The material for viral genotyping was stored in 10mM Tris-HCl, and the DNA of the HPV was extracted by using Genomic® DNA Purification kit (Promega...
In the case group, the DNA of the HPV was extracted from three 10-μm paraffin-embedded tissue sections from the biopsy specimens using the QiAamp DNA FFPE Tissue Kit (Qiagen GmbH, Hilden, Germany). The quality of the DNA target sequence and the absence of the inhibitors were tested in each sample by using the MY09/11 and GP5+/6+ primers for the amplification of the DNA viral and the PC04/GH20 primers for the internal control group. (human β-globin gene). Specific primers were used for HPV types 16, 18, 31 and 33.10 The data were collected using a specifically form developed by the own researcher. Data analysis was conducted by using Epi Info, version 7.1 (Atlanta, GA, USA). Initially, distribution tables were obtained of the frequencies of the categorical variables and by the frequency determined by the HPV genotypes.

To determine the association between the dependent variable, cervical adenocarcinoma, and the independent variables or predictors, the chi-square test and Fisher’s exact test were used when it was appropriate.

The odds ratios (OR) and 95% confidence intervals (95%CI) were calculated to determine the strength of the association between the dependent and independent variables as an estimate of relative risk. In all the steps of the analysis, a significance level of 5% was adopted and all p-values were two-tailed. Next, a multivariate, hierarchical stepwise logistic regression analysis was performed.12 A table was then constituted with the final variables that remained associated with adenocarcinoma.

This study was approved by the Ethics Research in Human Beings Committee at IMIP under the protocol number: CAAE 10815112.9.0000.5201. All the women were invited to participate in the study and only the women who voluntarily agreed to participate and signed an informed consent form were included.

Table 2 shows the factors that remained associated with cervical adenocarcinoma in the multivariate analysis, which included ≥40 years old (OR=2.95; CI95%=1.13-7.71; p=0.03); schooling ≤3 years (OR=2.34; CI95%=1.02-5.37; p=0.04) and the presence of HPV (OR=6.75; CI95%=2.41-18.91; p=0.0003). In addition, menopausal status (OR=4.76; CI95%=1.70-13.31; p=0.003), black (OR=6.71; CI95%=2.11-21.32; p=0.001) and have never undergone previous cervical cancer screening (OR=9.92; CI95%=2.41-40.81; p=0.001) also remained significantly associated with adenocarcinoma.

To study the associations of HPV types 16, 18, 31 and 33 with cervical adenocarcinoma, two different manners were evaluated: no other type of
Table 1
Factors associated with cervical adenocarcinoma.

| Variable                              | Adenocarcinoma | OR       | CI95%    | p       |
|---------------------------------------|----------------|----------|----------|---------|
|                                       | yes            | no       |          |         |
|                                       | n   | %      | n   | %      |       |         |
| First sexual intercourse              |     |        |     |        |       |         |
| < 20 years old                        | 40  | 71.4   | 177 | 68.1   | 1.17  | 0.62-2.21 |
| > 20 years old                        | 16  | 28.6   | 83  | 31.9   |       |         |
| Number of partners                    |     |        |     |        |       |         |
| < 2                                   | 40  | 71.2   | 147 | 56.5   | 1.92  | 1.02-3.61 |
| > 2                                   | 16  | 28.6   | 113 | 43.5   |       |         |
| Previous pregnancies                  |     |        |     |        |       |         |
| >5                                    | 18  | 30.0   | 28  | 10.8   | 3.55  | 1.80-6.99 |
| <5                                    | 42  | 70.0   | 232 | 89.2   |       |         |
| Previous use of hormonal contraceptives|     |        |     |        |       |         |
| Yes                                   | 23  | 39.7   | 189 | 73.0   | 0.24  | 0.13-0.44 |
| No                                    | 35  | 60.3   | 70  | 27.0   |       |         |
| Menopause                             |     |        |     |        |       |         |
| Yes                                   | 17  | 29.8   | 19  | 7.3    | 5.39  | 2.58-11.24 |
| No                                    | 40  | 70.2   | 241 | 92.7   |       |         |
| Condom use                            |     |        |     |        |       |         |
| Yes                                   | 1   | 1.8    | 20  | 7.7    | 0.21  | 0.03-1.63 |
| No                                    | 56  | 98.2   | 240 | 92.3   |       |         |
| Immunosuppressive drugs               |     |        |     |        |       |         |
| Yes                                   | 0   | 0      | 5   | 1.9    | -     | -       |
| No                                    | 60  | 100    | 255 | 91.2   |       |         |
| Chronic disease                       |     |        |     |        |       |         |
| Yes                                   | 41  | 65.1   | 95  | 36.7   | 3.22  | 1.81-5.72 |
| No                                    | 22  | 34.9   | 164 | 63.3   |       |         |
| STI                                   |     |        |     |        |       |         |
| Yes                                   | 6   | 9.8    | 47  | 18.4   | 0.48  | 0.19-1.19 |
| No                                    | 55  | 90.2   | 209 | 81.6   |       |         |
| Current smoker                        |     |        |     |        |       |         |
| Yes                                   | 3   | 5.1    | 25  | 9.6    | 0.50  | 0.15-1.73 |
| No                                    | 56  | 94.9   | 235 | 90.4   |       |         |
| Former smoker                         |     |        |     |        |       |         |
| Yes                                   | 13  | 22.0   | 52  | 22.2   | 0.99  | 0.49-1.97 |
| No                                    | 46  | 78.0   | 182 | 77.8   |       |         |
| Smokes                                |     |        |     |        |       |         |
| Yes                                   | 13  | 22.0   | 77  | 29.7   | 0.67  | 0.34-1.31 |
| No                                    | 46  | 78.0   | 182 | 70.3   |       |         |
| Cancer screening                      |     |        |     |        |       |         |
| Yes                                   | 17  | 29.3   | 6   | 2.3    | 17.5  | 6.54-47.12 |
| No                                    | 41  | 70.7   | 254 | 97.7   |       |         |
| HPV                                   |     |        |     |        |       |         |
| Yes                                   | 56  | 87.5   | 146 | 56.2   | 5.47  | 2.50-11.93 |
| No                                    | 8   | 12.5   | 114 | 43.8   |       |         |
| Age ≥40 years old                     |     |        |     |        |       |         |
| Yes                                   | 51  | 79.7   | 133 | 51.2   | 3.74  | 1.94-7.22 |
| No                                    | 13  | 20.3   | 127 | 48.8   |       |         |

*Chi-square test, **Fisher’s exact test, STI= sexually transmitted infection, OR: Odds Ratio, CI95% = 95% confidence interval, HPV= human papillomavirus, BMI= body mass index.
### Table 1

Factors associated with cervical adenocarcinoma.

| Variable                        | yes | %    | no  | %    | OR      | CI95%     | p    |
|---------------------------------|-----|------|-----|------|---------|-----------|------|
| Blackskin                       |     |      |     |      |         |           |      |
| Yes                             | 9   | 16.4 | 15  | 5.8  | 3.19    | 1.32-7.74 | 0.02**|
| No                              | 46  | 83.6 | 245 | 94.2 |         |           |      |
| BMI ≥25.0 kg/m²                  |     |      |     |      |         |           |      |
| Yes                             | 25  | 64.1 | 138 | 56.8 | 1.34    | 0.67-2.74 | 0.39* |
| No                              | 14  | 35.9 | 105 | 43.2 |         |           |      |
| Illiterate                      |     |      |     |      |         |           |      |
| Yes                             | 9   | 17.6 | 11  | 4.2  | 4.85    | 1.89-12.41| 0.004**|
| No                              | 42  | 82.4 | 249 | 95.8 |         |           |      |
| Schooling ≤3 years              |     |      |     |      |         |           |      |
| Yes                             | 27  | 52.9 | 45  | 17.3 | 5.37    | 2.84-10.16| <0.001*|
| No                              | 24  | 47.1 | 215 | 82.7 |         |           |      |
| No current partner              |     |      |     |      |         |           |      |
| Yes                             | 26  | 44.1 | 77  | 29.6 | 1.87    | 1.05-3.34 | 0.03* |
| No                              | 33  | 55.9 | 183 | 70.4 |         |           |      |
| Lives in Recife or in the       |     |      |     |      |         |           |      |
| metropolitan region              |     |      |     |      |         |           |      |
| Yes                             | 43  | 67.2 | 218 | 83.8 | 0.39    | 0.21-0.73 | 0.002*|
| No                              | 21  | 32.8 | 42  | 16.2 |         |           |      |

*Chi-square test. **Fisher’s exact test, STI= sexually transmitted infection, OR= Odds Ratio, CI95%= 95% confidence interval, HPV= human papillomavirus, BMI= body mass index.

### Table 2

Multivariate analysis of factors associated with cervical adenocarcinoma.

| Variables                        | Coefficient | Standard Error | OR     | CI95%    | p     |
|----------------------------------|-------------|----------------|--------|----------|-------|
| Age ≥40 years old                | 1.08        | 0.49           | 2.95   | 1.13-7.71| 0.03  |
| Schooling ≤3 years               | 0.85        | 0.42           | 2.34   | 1.02-5.37| 0.04  |
| HPV                              | 1.91        | 0.52           | 6.75   | 2.41-18.91| <0.001|
| Menopause                        | 1.56        | 0.52           | 4.76   | 1.70-13.31| 0.003 |
| Blackskin                        | 1.90        | 0.59           | 6.71   | 2.11-21.32| 0.001 |
| Never underwent screening        | 2.29        | 0.72           | 9.92   | 2.41-40.81| 0.001 |
| Constant                         | 4.80        | 0.62           |        |          | <0.001|

*Chi-square test, OR= Odds Ratio, CI95%= 95% confidence interval, HPV= human papillomavirus.
Table 3

HPV types associated with women with cervical adenocarcinoma.

| HPV                        | Women with adenocarcinoma n=64 | Healthy Women n=219 | OR          | CI95%        | p       |
|----------------------------|---------------------------------|---------------------|-------------|--------------|---------|
| 16 alone                   | 34 53.1%                        | 90 41.1%            | 1.62        | 0.93-2.84    | 0.09**  |
| 18 alone                   | 20 31.3%                        | 1 0.5%              | 99.1        | 12.96-757.78 | <0.001**|
| 31 alone                   | 33 51.6%                        | 40 18.3%            | 4.76        | 2.62-8.66    | <0.001* |
| 33 alone                   | 27 42.2%                        | 7 3.2%              | 22.10       | 8.97-54.45   | <0.001* |
| 16, 18 together            | 13 20.3%                        | 58 26.5%            | 0.71        | 0.36-1.39    | 0.32**  |
| 16, 31 together            | 7 10.9%                         | 14 6.4%             | 1.80        | 0.69-4.67    | 0.17**  |
| 16, 33 together            | 4 6.3%                          | 0 0%                | -           | -            | 0.004** |
| 16, 18 associated with other types | 3 4.7%                      | 0 0%                | -           | -            | 0.01**  |
| 16, 31 associated with other types | 14 21.9%                   | 1 0.5%              | -           | -            | <0.001**|
| 16, 33 associated with other types | 16 25.0%                   | 1 0.5%              | -           | -            | 0.007*  |
| 18, 31 together            | 2 3.1%                          | 1 0.5%              | 7.03        | 0.63-78.85   | 0.13**  |
| 18, 31 associated with other types | 14 21.9%                   | 1 0.5%              | 61.04       | 7.84-475.07  | <0.001**|
| 18, 32 together            | 1 1.6%                          | 0 0%                | -           | -            | 0.46**  |
| 18, 33 associated with other types | 12 18.8%                   | 0 0%                | -           | -            | <0.001**|
| 31, 33 together            | 5 7.8%                          | 0 0%                | -           | -            | 0.001** |
| 31, 33 associated with other types | 20 31.3%                   | 0 0%                | -           | -            | <0.001**|
| 16, 18, 31 together        | 9 14.1%                         | 0 0%                | -           | -            | <0.001**|
| 16, 18, 33 together        | 8 12.5%                         | 0 0%                | -           | -            | <0.001**|
| 16, 31, 33 together        | 12 18.8%                        | 0 0%                | -           | -            | <0.001**|
| 18, 31, 33 together        | 9 14.1%                         | 0 0%                | -           | -            | <0.001**|
| 16, 18, 31, 33 together    | 6 9.4%                          | 0 0%                | -           | -            | <0.001**|

*Chi-square test, **Fisher's exact test, OR= Odds Ratio, CI95%= 95% confidence interval, HPV= human papillomavirus.
HPV alone or in association to one or more types of HPV were detected in the same patient. Thus, we observed that HPV 18 presented a strong association with cervical adenocarcinoma (OR=99.1; CI95%=12.96-757.78) but only when associated with one or more types of HPV. It should be emphasized that HPV 18 alone was not observed in our sample. Conversely, the presence of HPV 16 alone (OR=0.71; CI95%=0.36-1.39; p=0.32) or together with one or more HPV types (OR=1.62; CI95%=0.93-2.84; p=0.09) did not show any association with adenocarcinoma. As for HPV 33, a significant association was found while alone (p=0.004) and in association with one or more other HPV types (OR=22.1; 95%CI=8.97-54.45) (Table 3).

Discussion

In this present study, we have observed that women aged ≥40 years old, who had ≤3 years of schooling, had the presence of HPV, particularly HPV 18 associated with other HPV types, menopause, blackskin and never have undergone cervical cancer screening were factors strongly associated with adenocarcinoma.

Studies report that the time of appearance of cervical adenocarcinoma has been decreasing over recent years. In this present study, women aged ≥40 years old and presented menopause were factors associated with adenocarcinoma, unlike in other studies in which this association was found in younger ages. This difference, along with the worldwide trends, may be due to delays in the diagnosis of adenocarcinoma in Brazil where, in fact, the access to healthcare services is often difficult and this may have contributed to this association.

Furthermore, as most of the patients in this study were diagnosed in the invasive phase, the age group involved may have been younger if earlier stages of the disease had been predominant. Epidemiological studies conducted between 1986 and 2005 revealed an increase in the incidence of cervical adenocarcinoma in women up to 35 years of age, particularly between 20 and 34 years old. While in 2007, a study conducted in Porto Alegre, Brazil, found that the patients’ mean age with adenocarcinoma was 53.2 years old, a figure similar to that in this study.

The association among schooling ≤3 years, blackskin and never have undergone cervical cancer screening is closely associated with low socioeconomic conditions of this population. This finding differs from other authors in which report an increase in the incidence of cervical adenocarcinoma in populations with a higher socioeconomic level.

It is important to emphasize that most of the studies on adenocarcinoma were conducted in developed countries, however, this study was carried out in a poor region of a developing country, in the Northeast of Brazil. Low socioeconomic level is associated with problems in seeking and having access to healthcare services; consequently, cervical cancer screening tests are not performed.

The lack of cervical cancer screening was an important factor for the presence of neoplasms, with an approximately 10-fold chance for women with cervical adenocarcinoma to have not undergone any kind of screening. This result shows the need for more effective screening program with better coverage similar to the developed countries. The lack of access to the healthcare services may have contributed in not performing the screening, thus, women with adenocarcinoma were, less likely, living in Recife or in the metropolitan area in the state of Pernambuco, where the coverage is better than in other areas of the state.

Obesity and the use of contraceptives are described as factors associated with adenocarcinoma, however, this association was not found. The lack of association may be due to a general profile of overweight people in this state. Moreover, this study evaluated overweight but not obesity. In relation to the duration of contraceptive use, it was not analyzed, and most studies have related the duration of use with the presence of the disease, although these results are controversial.

No significant associations were found for cervical adenocarcinoma in sexually transmitted infections or the use of immunosuppressive, possibly this information was missing on some records, for this is already known as a risk associated factor. Similarly, the use of condoms protect patients against adenocarcinoma; however, in our present study this association was not observed. As the data collection was retrospective, the information was not always available. In relation to smoking, there was no significant association in which corroborates with most of the studies.

The presence of HPV was 87.5% in the case groups. The literature refers to the presence of HPV 16 and 18 in up to 90% of the cases of adenocarcinoma in situ and in 92% of the cases of invasive adenocarcinoma. Among the types of HPV mostly found, HPV 18 was closely related with adenocarcinoma; however, it was always associated to some other type or more than one different HPV types. There were no findings of HPV 18 alone in either case or control groups. HPV 33 with no association...
to other HPV types, but some types of associations were found only in the case group, and there are no other similar results observed in the researched literature. Studies suggest that association between different HPV types is important for the occurrence of adenocarcinoma.\textsuperscript{21,22} The present findings showed that the likelihood of adenocarcinoma was greater when HPV 18 and 31 were associated with other types. The literature showed that HPV 16 and 18 together are responsible for 70% of the cervical cancer cases worldwide.\textsuperscript{23}

In a Brazilian study, the most common HPV types found in women with adenocarcinoma were HPV 16 (77.6%), 18 (12.3%), 31 (8.8%), 33 (7.1%) and 35 (5.9%), like the findings in this present study.\textsuperscript{22} However, in that study only 28 cases consisted of adenocarcinoma. Other data in the literature have reported the most common types of HPV in adenocarcinoma are HPV 16 (41.6%), 18 (38.7%), 45 (7.0%), 31 (2.2%) and 33 (2.1%), in which did not occur in the present study.\textsuperscript{23}

There are some methodological limitations to this study. As this study is retrospective, there were some difficulties in the research of some information missing. And additionally, 13 cases were excluded because tissue paraffin blocks for genotyping were not found. Another limitation concerns the consequence of using different HPV typing methods for the cases and controls. Nevertheless, it should be emphasized that amplification of the human beta-globin gene was performed in both groups, guaranteeing the presence of DNA in the sample despite the difficulties described in the literature. All the paraffin-embedded samples case group were tested positive for the human beta-globin gene.\textsuperscript{24}

In conclusion, further studies are required to correlate HPV types in women with cervical adenocarcinoma and to evaluate their variation in each region precisely at the time of diagnosis, making this investigation part of hospitals routine. These studies should contribute to provide further knowledge on the behavior of HPV in cases of cervical adenocarcinoma. Likewise, it is important to continue analyzing the associated factors in new epidemiological studies. Since the frequency of adenocarcinoma is low, the optimal study design is a case-control study such as this one, because the design study are more factual to determine these factors. We believe that this scenario could change if vaccination coverage against HPV types 6, 11, 16 and 18 were 100%, since HPV 18 is closely associated with adenocarcinoma. However, it is generally accompanied by other types such as HPV 16, 31 and 33, as found in this study. In the future changes may occur both in the viral types and in the variants of these types and even vaccination campaigns may require more regionalized re-organization.

**Contribuições dos autores**

Souza ASR and Amorim MMR - performed all the data handling and statistical analyses. Souza PRE contributed to the methodological discussions. Costa TML and Souza ASR - drafted the first version of the article. Souza ASR, Amorim MMR, Costa TML, Souza PRE, Heráclio S, Souza GFA and Lubambo N revised the article on several occasions. All authors approved the final version of the manuscript.

**References**

1. IARC (Intenational Agency for Resaerch on Cancer). WHO (World Health Organization). Global Cancer Observatory 2012. [cited 2015 Mar 15]. Available from: http://globocan.iarc.fr/Default.aspx
2. INCA (Instituto Nacional de Cáncer José Alencar Gomes da Silva). Controle do câncer do colo do útero - Conceito e magnitude. Rio de Janeiro: INCA, 2019. [acesso em 26 Mar 2019]. Disponível em: www.inca.gov.br/controle-do-cancer-do-colo-do-utero/conceito-e-magnitude
3. INCA (Instituto Nacional de Cáncer José Alencar Gomes da Silva). Coordenação de Prevenção e Vigilância. Divisão de Deteção Precoce e Apoio à Organização de Rede. Diretrizes brasileiras para o rastreamento do câncer do colo do útero. 2ed. Rio de Janeiro: INCA, 2016. p.114.
4. Hou J, Goldberg GL, Qualls CR, Kuo DYS, Forman A, Smith HO. Risk factors for poor prognosis in microinvasive adenocarcinoma of the uterine cervix (IA1 and IA2): a pooled analysis. Gynecol Oncol. 2011; 121 (1):135–42.
5. Smith HO, Tiffany MF, Qualls CR, Key CR. The Rising Incidence of adenocarcinoma Relative to Squamous Cell Carcinoma of the Uterine Cervix in the United States - a 24-year population-based study. Gynecol Oncol. 2000; 78 (2): 97–105.
6. Lacey JV, Swanson CA, Brinton LA, Altekruse SF, Barnes WA, Gravitt PE, Greenberg MD, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Kurman RJ, Hildesheim A. Obesity as a potential risk factor for adenocarcinomas and squamous cell carcinomas of the uterine cervix. Cancer. 2003; 98 (4): 814–21.
7. Liu S, Semenciw R, Mao Y. Cervical cancer: the increasing incidence of adenocarcinoma and adenosquamous carcinoma in younger women. CMAJ. 2001; 164 (8): 1151–2.
8. Pirog EC, Lloversas B, Molijn A, Tous S, Guimerà N, Alejo M, Clavero O, Klaustermeier J, Jenkins D, Quint WG, Xavier Bosch F, Alemany L, de Sanjose S, RIS HPV TT study group. HPV prevalence and genotypes in different
Human papillomavirus and risk factors for cervical adenocarcinoma

histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol. 2014; 27 (12): 1559–67.

9. Eifel P, Burke TW, Morris M, Smith TL. Adenocarcinoma as an independent risk factor for disease recurrence in patients with stage IB cervical carcinoma. Gynecol Oncol. 1995; 59 (1): 38–44.

10. Mendonça VG, Guimarães MJB, de Lima Filho JL, de Mendonça CG, Martins DBG, Crovella S, Alencar LCA. Human papillomavirus cervical infection: viral genotyping and risk factors for high-grade squamous intraepithelial lesion and cervix cancer. Rev Bras Ginecol Obstet. 2010; 32 (10): 476–85.

11. Bornstein J, Bentley J, Bösze P, Girardi F, Haefner H, Menton M, Perrott M, Prendiville W, Russell P, Sideri M, Strander B, Tatti S, Torne A, Walker P. 2011 colposcopic terminology of the International Federation for Cervical Pathology and Colposcopy. Obstet Gynecol. 2012; 120 (1): 166–72.

12. Victora CG, Huttly SR, Fuchs SC, Olinto MT. The role of conceptual frameworks in epidemiological analysis: a hierarchical approach. Int J Epidemiol. 1997; 26 (1): 224–7.

13. Schwartz SM, Weiss NS. Increased incidence of adenocarcinoma of the cervix in young women in the United States. Am J Epidemiol. 1986; 124 (6): 1045–7.

14. Cambruazzi E, Zettler CG PC. Endocervical adenocarcinoma in Porto Alegre and metropolitan region: morphology and prevalence. Rev AMRIGS. 2005; 49 (4): 27–33.

15. Wang SS, Sherman ME, Silverberg SG, Carreon JD, Lacey J V, Zaino R, Kurman RJ, Hildesheim A. Pathological characteristics of cervical adenocarcinoma in a multi-center US-based study. Gynecol Oncol. 2006; 103 (2): 541–6.

16. Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah K V, Walboomers JM, Herrero R, Franceschi S, International Agency for Research on Cancer. Multicentric Cervical Cancer Study Group. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study. Lancet 2002; 359 (9121): 1085–92.

17. Pinho CP, Diniz AS, Arruda IK, Batista Filho M, Coelho PC, Sequeira LA, Lira PI. Prevalence of abdominal obesity and associated factors among individuals 25 to 59 years of age in Pernambuco State, Brazil. Cad Saúde Pública. 2013; 29 (2): 313–24.

18. Madeleine MM, Daling JR, Schwartz SM, Shera K, McKnight B, Carter JJ, Wipf GC, Critchlow CW, McDougal JK, Porter P, Galloway DA. Human papillomavirus and long-term oral contraceptive use increase the risk of adenocarcinoma in situ of the cervix. Cancer Epidemiol Biomarkers Prev. 2001; 10 (3): 171–7.

19. Altekruse SF, Lacey J V, Brinton LA, Gravitt PE, Silverberg SG, Barnes WA Jr, Greenberg MD, Hadjimichael OC, McGowan L, Mortel R, Schwartz PE, Hildesheim A. Comparison of human papillomavirus genotypes, sexual, and reproductive risk factors of cervical adenocarcinoma and squamous cell carcinoma: Northeastern United States. Am J Obstet Gynecol. 2003; 188 (3): 657–63.

20. Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, Smith JS, Snijders PJ, Meijer CJ, Bosch FX, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J Natl Cancer Inst. 2006; 98 (5): 303–15.

21. Ault KA, Joura EA, Kjaer SK, Iversen O-E, Wheeler CM, Perez G, Brown DR, Koutsy LA, Garland SM, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Majewski S, Muñoz N, Sings HL, Harkins K, Rutkowski MA, Haupt RM, Garner EJ, FUTURE I and II Study Group. Adenocarcinoma in situ and associated human papillomavirus type distribution observed in two clinical trials of a quadrivalent human papillomavirus vaccine. Int J Cancer. 2011; 128 (6): 1344–53.

22. Oliveira CM, Fregnani JHTG, Carvalho JP, Longatto-Filho A, Levi JE. Human papillomavirus genotypes distribution in 175 invasive cervical cancer cases from Brazil. BMC Cancer. 2013; 13 (357): 1-8.

23. Pimenta JM, Galindo C, Jenkins D, Taylor SM. Estimate of the global burden of cervical adenocarcinoma and potential impact of prophylactic human papillomavirus vaccination. BMC Cancer. 2013; 13 (553): 1-12.

24. Simonato LE, Garcia JF, Nunes CM MG. Evaluation of two methods of DNA extraction from paraffin-embedded material for PCR amplification. J Bras Patol Med Lab. 2007; 43 (2): 121–7.

Received on January 15, 2019
Final version presented on April 15, 2019
Approved on June 19, 2019